Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immutep Ltd has received Orphan Drug Designation from the FDA for eftilagimod alfa in the treatment of Soft Tissue Sarcoma, a rare cancer with significant unmet medical need. This designation is intended to encourage the development of therapies for rare diseases and may provide various benefits including regulatory support and market exclusivity. The decision is based on promising clinical data from the Phase II EFTISARC-NEO trial, which showed significant results in patients with resectable soft tissue sarcoma. CEO Marc Voigt expressed optimism about the potential for efti in treating this challenging cancer type.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
- Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti
- New investigator-initiated Phase II trial for Efti
- Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025
Earlier from Immutep
- Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
- Update on Phase I Study of IMP761 for Autoimmune Diseases
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
- TACTI-004 to be discontinued following futility analysis
- Reinstatement to Quotation
Later from Immutep
- Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
- Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- Immutep Receives Nasdaq Notice of Bid Price Deficiency
- Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients
- Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep